Drug May Ease Symptoms of Juvenile Arthritis
TOOLBOX   Resize
 Save/Share +
COMMENT
 Discussion Policy
 CLOSE
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.
|
TUESDAY, July 15 (HealthDay News) -- Children suffering from juvenile arthritis who haven't had luck with other treatments may benefit from a drug called Orencia (abatacept).
The conclusions follow from a randomized trial of 122 patients aged 6 to 17 from 45 centers in Europe and in the United States. All participants had a history of juvenile idiopathic arthritis and had at least five joints with active disease. All had tried and failed at least one previous drug.
Participants were randomly assigned to receive 10 milligrams per kilogram of Orencia at 28-day intervals for six months or until the arthritis flared up, or a placebo given on the same schedule.
Just over half (53 percent) of patients on the placebo and 20 percent of those on Orencia experienced an exacerbation of their condition. The odds of a flare-up in patients on Orencia were only 31 percent of that for patients on the placebo. Side effects were similar.
According to the Arthritis Foundation, juvenile idiopathic arthritis is a family of diseases involving chronic joint inflammation. Current drugs seem to fall short of what's needed, with up to 85 percent of children expected to relapse.
The study was conducted by researchers at the Istituto G Gaslini Pediatria II, Largo Gaslini, in Genova, Italy, and was published online inThe Lancet.
An accompanying commentary questioned the design of the study, suggesting that it might overestimate the benefit of the drug while understating its side effects.
More information
The Arthritis Foundation has more on juvenile arthritis.
SOURCE:The Lancetpress release, July 15, 2008
